Lv39
228 积分 2025-03-07 加入
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
6小时前
已完结
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
6小时前
已完结
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
6小时前
已完结
Phase 3 ESSENCE Trial: Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
16小时前
已关闭
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
18小时前
已完结
ASSOCIATION BETWEEN ANXIETY AND DEPRESSION IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
16天前
已关闭
Partial MCT1 invalidation protects against diet-induced non-alcoholic fatty liver disease and the associated brain dysfunction
16天前
已完结
Association of metabolic dysfunction-associated fatty liver disease with kidney disease
29天前
已完结
New Nonalcoholic Fatty Liver Disease and Fibrosis Progression Associate With the Risk of Incident Chronic Kidney Disease
29天前
已完结
Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants
29天前
已完结
皖公网安备34019202002308
